Reviewer #3 (Public Review):
Caligaris and colleagues show a new mechanism by which AMPK/Snf1 inhibits TORC1 signaling during glucose starvation. They propose that under glucose starvation, Snf1 inhibits the unscheduled activation of TORC1 by phosphorylating Pib2 and Sch9, upstream and downstream effectors of TORC1. The study also provides a resource for novel substrates of Snf1 which can be useful for future studies. Specific comments are below.
1. Conceptually, the manuscript shows that Snf1 activity is important for the acute inhibition of TORC1 during glucose starvation. However, this is mainly restricted to 10 and 15 minutes of glucose starvation. After 20 minutes, TORC1 is inhibited by some unknown mechanisms independent of Snf1 (Hughes Hallet et al). This raises concern regarding the physiological relevance of Snf1-mediated TORC1 inhibition during acute glucose stress. The authors show that this regulation is important for the survival of cells under TORC1 inhibition. How do the authors envision that the acute role of Snf1 plays an important long-term physiological relevance during rapamycin treatment? Providing more support for the physiological relevance of this regulation will make this study of interest to a broad readership.
2. Another major concern of the manuscript is the inconsistencies between the various representative immunoblots and their quantifications. The effect of AMPK activity on TORC1 signaling under glucose starvation seems very subtle. A few specific concerns are mentioned below:
a) In figure 1A, the increase in TORC1 activity upon inhibition of analogue sensitive Snf1as by 2NM-PP1 is very marginal. Although quantification shows a significant increase, a representative western blot figure should be shown.
b) Does deleting Snf1 itself have any effect on TORC1 activity? Lane 4 of figure 1A shows reduced activity compared to lane 1.
c) To show the effect of Snf1 on the repression of TORC1, the time-course experiments are run on two separate gels in figure 1C. Hence, it is difficult to compare the effect of Snf1 on unscheduled reactivation of TORC1 under glucose starvation.
d) In figure 1E, the effect of Reg1 deletion on TORC1 activity seems minor as both phospho- and total levels of Sch9 are reduced.
Since further mechanistic insights are based on these initial findings of figure 1, solidifying these observations is very important.
3. In figure S1, the analogue sensitive Snf1as shows significant reduction in its activity (reduced S79 phosphorylation of ACC1-GFP). This raises the concern of whether this genetic background is an ideal system to resolve the mechanism of TORC1 suppression.
4. In figure 2, during glucose restimulation, there is increased retention of Snf1as-pThr210 in the presence of 2NM-PP1. This suggests that the upstream glucose sensing pathway as well as Snf1 might be more active than in DMSO-treated cells. This also raises concerns regarding the suitability of the genetic background for the study. Can authors comment on why this phosphorylation persists? Does the phosphoproteomic analysis give any hint for this phenotype?
5. In figure 4H, where authors claim reduced binding of Kog1 to Pib2SESE, levels of Kog1 in input are also reduced. Can authors provide further support using colocalization studies? Also, does Pib2SESE has any defect in forming Kog1 bodies?
6. In figure 5F, where the authors claim the Sch9SE mutant has lower TORC1 activity, the difference is very minor. Furthermore, corresponding lanes also show reduced levels of Snf1as expression. Hence, improved blots are required here. Also, an in vitro kinase assay with full-length Sch9 KD with and without the Ser288 mutation could solidify the observation that phosphorylation of Ser288 indeed affects TORC1-mediated phosphorylation.
7. In figure 6E, the Sch9SE mutant shows no effect in the presence of rapamycin. Thus, in vivo, phosphorylation at Ser288 may not be perturbing the phosphorylation of Sch9 by TORC1.
8. According to the author's proposed mechanism, TORC1 activity in Pib2SASA or Pib2SASA/Sch9SA backgrounds should be higher during glucose starvation compared to the control strains. However, glucose starvation shows a similar level of reduction in TORC1 activity in these backgrounds. This raises concern regarding the proposed mechanism. The authors mainly base their conclusions on Ser to Glutamate mutants. The authors should be cautious that Ser to Glutamate changes may also affect the protein structure which can confer similar phenotypes. How do the authors justify this discrepancy?